Benzinga | Apr 21, 2021 08:03AM EDT

Ayala Pharmaceuticals Announces First Patient Dosed In Phase 1 Clinical Trial Of AL102 In Combination With BCMA Targeting Agent, WVT078, In Patients With Relapsed/Refractory Multiple Myeloma

Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced the dosing of the first patient in the ongoing Phase 1 clinical trial evaluating its potent investigational gamma secretase inhibitor (GSI), AL102, in combination with Novartis' investigational anti-B-cell maturation antigen (BCMA) agent, WVT078, for the treatment of patients with relapsed and/or refractory multiple myeloma (MM).